Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s stock price traded down 3.5% during trading on Thursday . The stock traded as low as $202.85 and last traded at $205.25. 1,618 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 2,749 shares. The stock had previously closed at $212.80.
Genmab A/S Price Performance
The company’s 50 day simple moving average is $220.80 and its 200 day simple moving average is $248.86. The firm has a market cap of $13.42 billion, a price-to-earnings ratio of 19.74 and a beta of 1.03.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- How to trade using analyst ratings
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- What is the Australian Securities Exchange (ASX)
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
